FY2025 EPS Estimates for Ironwood Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, June 26th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $0.72 per share for the year, up from their previous forecast of $0.71. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS and FY2026 earnings at $0.96 EPS.

Several other equities analysts have also recently issued reports on IRWD. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 18th. Craig Hallum cut their price target on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $18.40.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD opened at $6.52 on Monday. Ironwood Pharmaceuticals has a one year low of $5.47 and a one year high of $15.70. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -0.96 and a beta of 0.52. The company has a 50-day simple moving average of $6.72 and a 200-day simple moving average of $9.68.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative return on equity of 28.45% and a negative net margin of 254.41%. The business had revenue of $74.90 million for the quarter, compared to analysts’ expectations of $105.75 million. During the same quarter last year, the business posted $0.25 earnings per share. The business’s revenue was down 28.0% on a year-over-year basis.

Insider Transactions at Ironwood Pharmaceuticals

In related news, Director Julie Mchugh sold 22,766 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $6.29, for a total transaction of $143,198.14. Following the transaction, the director now owns 139,528 shares of the company’s stock, valued at $877,631.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Catherine Moukheibir sold 44,426 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total transaction of $282,549.36. Following the sale, the director now owns 84,207 shares of the company’s stock, valued at approximately $535,556.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie Mchugh sold 22,766 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $6.29, for a total value of $143,198.14. Following the completion of the transaction, the director now directly owns 139,528 shares of the company’s stock, valued at $877,631.12. The disclosure for this sale can be found here. Company insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in IRWD. Signaturefd LLC increased its position in Ironwood Pharmaceuticals by 61.4% during the 4th quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 822 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Ironwood Pharmaceuticals by 331.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,900 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,645 shares during the period. Quadrant Capital Group LLC boosted its position in Ironwood Pharmaceuticals by 68.8% during the fourth quarter. Quadrant Capital Group LLC now owns 8,578 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 3,497 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $91,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.